Sage Therapeutics Inc (SAGE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sage Therapeutics Inc (SAGE) has a cash flow conversion efficiency ratio of -0.159x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-58.69 Million) by net assets ($368.74 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Sage Therapeutics Inc's balance sheet to measure how much of total assets are equity-financed.
Sage Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Sage Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Sage Therapeutics Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Sage Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sage Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cytek Biosciences Inc
NASDAQ:CTKB
|
-0.008x |
|
AQUILA PART PROD COM
RO:AQ
|
0.061x |
|
Chularat Hospital Public Company Limited
BK:CHG
|
0.028x |
|
Shandong Binzhou Bohai Piston Co Ltd
SHG:600960
|
-0.045x |
|
Vulcan Steel Ltd
AU:VSL
|
0.138x |
|
Ethan Allen Interiors Inc
NYSE:ETD
|
0.032x |
|
Sichuan Expressway Company Limited
F:EXF1
|
0.060x |
|
SAPPI LTD ADR/1 RC 1
F:SPIA
|
0.023x |
Annual Cash Flow Conversion Efficiency for Sage Therapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Sage Therapeutics Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see Sage Therapeutics Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $465.09 Million | $-267.19 Million | -0.575x | +15.03% |
| 2023-12-31 | $799.53 Million | $-540.59 Million | -0.676x | -84.10% |
| 2022-12-31 | $1.25 Billion | $-460.04 Million | -0.367x | -67.91% |
| 2021-12-31 | $1.73 Billion | $-378.18 Million | -0.219x | -168.23% |
| 2020-12-31 | $2.07 Billion | $664.28 Million | 0.321x | +157.27% |
| 2019-12-31 | $944.65 Million | $-528.71 Million | -0.560x | -85.29% |
| 2018-12-31 | $862.97 Million | $-260.67 Million | -0.302x | +34.50% |
| 2017-12-31 | $475.48 Million | $-219.28 Million | -0.461x | -43.20% |
| 2016-12-31 | $368.52 Million | $-118.68 Million | -0.322x | +20.86% |
| 2015-12-31 | $173.69 Million | $-70.68 Million | -0.407x | -83.41% |
| 2014-12-31 | $121.89 Million | $-27.04 Million | -0.222x | -139.94% |
| 2013-12-31 | $-31.54 Million | $-17.52 Million | 0.555x | -16.65% |
| 2012-12-31 | $-13.39 Million | $-8.93 Million | 0.666x | -- |
About Sage Therapeutics Inc
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric m… Read more